Repligen Corporation (NASDAQ:RGEN)‘s stock had its “hold” rating restated by equities research analysts at Jefferies Group LLC in a research report issued on Thursday. They presently have a $40.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s target price points to a potential downside of 7.24% from the stock’s current price.

Several other research analysts also recently issued reports on the company. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. BidaskClub upgraded Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, June 6th. Janney Montgomery Scott lifted their price objective on Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. Finally, William Blair assumed coverage on Repligen Corporation in a research report on Friday, July 21st. They set an “outperform” rating for the company. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $42.00.

Repligen Corporation (RGEN) traded up 0.28% during midday trading on Thursday, hitting $43.12. The stock had a trading volume of 202,331 shares. The firm has a market cap of $1.61 billion, a P/E ratio of 84.38 and a beta of 1.21. The stock has a 50-day moving average price of $41.85 and a 200 day moving average price of $38.55. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The company had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. During the same period last year, the firm earned $0.16 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. On average, equities analysts anticipate that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Repligen Corporation (RGEN) Stock Rating Reaffirmed by Jefferies Group LLC” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/repligen-corporation-rgen-stock-rating-reaffirmed-by-jefferies-group-llc.html.

Several institutional investors have recently modified their holdings of the stock. Lord Abbett & CO. LLC raised its position in shares of Repligen Corporation by 330.9% during the 2nd quarter. Lord Abbett & CO. LLC now owns 851,360 shares of the biotechnology company’s stock worth $35,280,000 after purchasing an additional 653,791 shares during the last quarter. North Star Asset Management Inc. raised its position in shares of Repligen Corporation by 32.5% during the 2nd quarter. North Star Asset Management Inc. now owns 20,549 shares of the biotechnology company’s stock worth $852,000 after purchasing an additional 5,040 shares during the last quarter. Piedmont Investment Advisors LLC acquired a new position in shares of Repligen Corporation during the 2nd quarter worth approximately $331,000. Castleark Management LLC acquired a new position in shares of Repligen Corporation during the 2nd quarter worth approximately $7,592,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Repligen Corporation by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,402 shares of the biotechnology company’s stock worth $1,095,000 after purchasing an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 97.91% of the company’s stock.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.